Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 25, 2022 - The FDA approved Kashiv Biosciences’ Releuko (filgrastim-ayow), biosimilar to Amgen’s Neupogen® (filgrastim).
Download PDF
Return to publications
